GlassScriptPhysician profile
Charles L Pearson
NPI 1801806153
$1,102.35
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $177 · 2021: $122.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.13 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $187.06 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $121.83 | 2021 | |
| Ucb, INC. | $110.87 | 2019-2020 | |
| Glaxosmithkline, LLC. | $97.33 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $54.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $49.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $46.60 | 2019 | |
| Insmed, INC. | $34.15 | 2019-2020 | |
| Pfizer INC. | $25.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.52 | 2019 | |
| Chiesi USA, INC. | $20.38 | 2019 | |
| Mylan Specialty L.P. | $17.75 | 2020 | |
| Cook Medical LLC | $16.26 | 2019 | |
| La Jolla Pharmaceutical Company | $15.13 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $15.09 | 2020 | |
| Allergan, INC. | $14.29 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.12 | 2019 | |
| Merck Sharp & Dohme LLC | $11.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.